论文部分内容阅读
一、引言1961年Schlipkoter报导聚2-乙烯吡啶氮氧化物(PVNO,P_(204))对实验性矽肺的进展有显著的抑制作用。近年还观察到它有使矽肺胶元纤维退化、变性、使矽结节减少的作用。我国于1967年开始了聚2-乙烯吡啶氮氧化物(以下简称克矽平)的临床治疗。应用肌肉注射(剂量8毫克/公斤·周)或并用雾化吸入,通过多年观察,没有动物实验疗效好,两者差别较大。考虑到可能是用药剂量对临床疗效的影响,因此进行了大剂量静脉注射给药的疗效研究。
I. INTRODUCTION Schlipkoter reported in 1961 that poly (2-vinylpyridine) nitrogen oxide (PVNO, P_ (204)) significantly inhibited the progression of experimental silicosis. In recent years, it has also been observed that it has to silicosis yuan fiber degeneration, degeneration, so that the reduction of silicon nodules role. China started in 1967 Poly-2-vinyl pyridine nitrogen oxides (hereinafter referred to as Ke Si-ping) clinical treatment. By intramuscular (dose 8 mg / kg · week) or inhalation by inhalation, after years of observation, there is no good effect of animal experiments, the two differ greatly. Taking into account the possible dose of the clinical effect of the impact, so the high dose intravenous administration of efficacy study.